Latest discoveries! What is the neutralizing antibody that vaccine sits into a global asset?

China's new crown vaccine will be the world's public product President Xi Jinping announced at the opening ceremony of the 73rd World Health Organization video conference video conference: China's new crown vaccine research and development is completed and put into use, will be the world's public products, to achieve the vaccine in developing countries to achieve the accessibility and affordability of China's contribution.
China's Consino recombinant vaccine (adenovirus vector vaccine) is in the first tier of global vaccine research and development, has been approved by Health Canada on the recombinant vaccine (adenovirus vector) "Ad5-nCoV" clinical trial application.
, the mRNA vaccine, which is part of the first echelon of vaccine development, has also been a breakthrough in recent days.
mRNA vaccine breakthrough 18, Moderna published its new crown mRNA vaccine mRNA-1273 early human trial data: 45 subjects all produced antibodies, the first 8 produced neutral antibodies, the minimum dose (25 micrograms) in the 43rd day of the trial in the body antibody level and the virus infection patients recovered antibody level, and 100 micrograms of the group significantly exceeded this level, and the test did not have adverse reactions.
the highest dose of 250 micrograms will not be used in future clinical trials because of severe injection point allergies and systemic reactions in volunteers.
mRNA-1273 was developed in collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and biotech company Moderna.
the vaccine does not contain coronaviruses, but instead uses mRNA to direct the body to produce proteins similar to the surface of the new coronavirus in order to trigger an immune response and prevent infection.
mRNA vaccine compared to traditional vaccines, the biggest advantage is speed, in addition, also do not need additional adjuvants, good safety, relatively convenient production process, can be mass production, Sanofi, Fosun Pharma and so on in the mRNA vaccine field have layout.
's ever-developed antibodies To the Chinese team on The Hot Search on May 18, the U.S. journal Science published an online paper entitled "A non-competitive human-derived neutralized antibody can block the combination of COVID-19 virus and its receptor ACE2", saying they have found two human-derived monoclonal antibodies that can effectively block the new coronavirus infection, which are expected to be used in the development of anti-new coronaviruses and vaccines.
topic, that is, rush Baidu hot search list! Continuously developed neutralantibodies for the new coronavirus neutralizing antibody research and development, there are also a number of domestic enterprises through independent research and development or cooperative research and development of the way to carry out research.
the Golden Triangle of scientific research in Beijing (Tsinghua, Peking University and the Chinese Academy of Sciences) have also cooperated with enterprises, the Chinese Academy of Sciences and Junshi Biological Cooperation, Tsinghua University and Teng Shengbo Pharmaceutical Cooperation, Peking University and Yiqiu Shenzhou / Pharmaceutical Biology Cooperation have developed therapeutic candidate antibodies in a short period of time.
in addition, Jimin trust, Cinda Bio, Chengdu Shengshi Junlian, etc. are also in their own platform to carry out research and development.
before that, Sorrento Therapeutics, an innovative Chinese-led drug maker, announced that it had found an antibody that blocks the binding of the new coronavirus to cells, and that it had been shown to be 100% effective in the laboratory.
100% effective, whether the stock price speculation or indeed, wait for the article after the official publication of the data disclosure. what exactly is the highly-watched neutralantibodies of the
? Studies have shown that the new coronavirus is an RNA virus with a pungent S protein on its shell.
the new coronavirus invades cells, the S protein binds to the surface receptor ace2 of the human cell, then enters the cell, replicates it in the cell, reassembles it into a large number of new viruses, and continues to infect other cells, thus capturing the human body.
simply, to prevent the replication of viral cells, you need to have a substance can block the virus and cell surface receptor binding, said the bad point is to find another object for the virus, this "object" first combined with the virus, so that the cell is single, and then can not infect cells, harm the human body.
this "object" is what we call neutralizing antibodies.
serum (pulp) therapy used in china's fight against the outbreak of new coronary pneumonia is essentially an antibody therapy.
note that neutralizing antibodies is not a vaccine, the vaccine is the use of antigens (bacteria/viruses) to stimulate human cells, induce human cells to produce antibodies;
combined, high-quality neutralizing antibodies can be used in the treatment of neo-coronary pneumonia, and are safer, more targeted, and can also be used for short-term prevention, even if the outbreak persists and repeats, the neutralizing antibodies of this similar drug will be more effective than plasma therapy.
.